

Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference

July 3, 2008 1:50 PM ET

SOUTH SAN FRANCISCO, Calif., July 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at the upcoming Collins Stewart Fourth Annual Growth Conference at 2:30 p.m. Eastern Time on July 8, 2008 in New York, NY.

Interested parties may access a webcast of the presentation by visiting the Sunesis website at <http://ir.sunesis.com>. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin (formerly SNS-595), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

SOURCE Sunesis Pharmaceuticals, Inc.

<http://www.sunesis.com>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX